2d illustrations and photos/iStock via Getty Images Clinical-stage biotechnology company Metsera ( MTSR ) priced its initial public offering of ~15.28M shares at a price to the public of $18.00 per share.
The gross proceeds from the offering are expected to be approximately $275M. Metsera’s common stock is.